Who Owns Arrowhead Pharmaceuticals Stock?
NASDAQ: ARWRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 85.39%
- Held by insiders
- 3.66%
- Institutional holders
- 656
- Institutions 85.4%
- Insiders 3.7%
- Public and other 11.0%
Who owns Arrowhead Pharmaceuticals stock?
Institutional investors own about 85.4% of Arrowhead Pharmaceuticals's shares, spread across 656 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 3.66% of ARWR.
The largest institutional holders are Blackrock Inc. (10.53%), Avoro Capital Advisors LLC (8.06%) and FMR, LLC (5.71%). Together, the top 10 institutions control 47.6% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their ARWR positions and 5 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ARWR
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 14.83M | 10.53% | -18.3% |
| Avoro Capital Advisors LLC | 11.36M | 8.06% | +6.1% |
| FMR, LLC | 8.04M | 5.71% | +10.6% |
| Vanguard Portfolio Management LLC | 6.35M | 4.51% | -11.1% |
| Vanguard Capital Management LLC | 6.11M | 4.34% | +1.3% |
| State Street Corporation | 5.69M | 4.04% | -12.3% |
| NORGES BANK | 3.90M | 2.77% | +128.6% |
| Invesco Ltd. | 3.88M | 2.76% | +18.4% |
| Geode Capital Management, LLC | 3.53M | 2.51% | -17.5% |
| Fred Alger Management, LLC | 3.30M | 2.34% | -1.2% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ARWR
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 4.93M | 3.50% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.25M | 3.01% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 3.07M | 2.18% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.60M | 1.85% |
| Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Momentum ETF | 1.79M | 1.27% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.77M | 1.26% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.61M | 1.15% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.48M | 1.05% |
| SPDR S&P MIDCAP 400 ETF TRT-State Street SPDR S&P Mid Cap 400 ETF TRT | 1.03M | 0.73% |
| iShares Trust-iShares Biotechnology ETF | 990.76K | 0.70% |
Frequently asked questions
Who is the largest shareholder of Arrowhead Pharmaceuticals?
Blackrock Inc. is the largest institutional shareholder of ARWR, owning 10.53% of shares outstanding (14.83M shares) as of its latest 13F filing.
What percentage of Arrowhead Pharmaceuticals is owned by institutions?
Institutions own about 85.4% of ARWR shares and 88.6% of the public float.
How much of Arrowhead Pharmaceuticals do insiders own?
Insiders, such as officers and directors, own about 3.66% of ARWR shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.